Lexatumumab tolerated for pediatric solid tumors

Lexatumumab tolerated for pediatric solid tumors
Lexatumumab, an agonistic, full human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2, is well tolerated and may lessen certain clinical symptoms in some pediatric patients with solid tumors, according to a study published online Oct. 15 in the Journal of Clinical Oncology.

(HealthDay)—Lexatumumab, an agonistic, full human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2, is well tolerated and may lessen certain clinical symptoms in some pediatric patients with solid tumors, according to a study published online Oct. 15 in the Journal of Clinical Oncology.

Melinda S. Merchant, M.D., Ph.D., from the in Bethesda, Md., and colleagues conducted a phase I dose-escalation study to examine the safety, tolerability, pharmacokinetics, and immunogenicity of lexatumumab for recurrent or progressive solid tumors. Doses of 3, 5, 8, and 10 mg/kg were administered once every two weeks to 24 patients age 21 years of age and younger.

The researchers found that, over all four planned dose levels, the patients received a total of 56 cycles of lexatumumab. During the second cycle, one patient had grade 2 pericarditis consistent with radiation recall and one patient developed grade 3 pneumonia with hypoxia. For three to 24 cycles, five patients experienced stable disease. There were no complete or partial responses but evidence of antitumor activity was noted in several patients, including one patient with recurrent progressive osteosarcoma who experienced resolution of clinical symptoms and positron emission tomography activity, which was ongoing more than one year after cessation of therapy. There was a dramatic biomarker response seen in one patient with hepatoblastoma.

"In conclusion, this study demonstrates that lexatumumab is well tolerated in heavily pretreated pediatric patients with solid tumors," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Dose-escalated cetuximab tolerated in colorectal cancer

Jul 05, 2012

(HealthDay) -- For patients with irinotecan-refractory metastatic colorectal cancer (CRC), dose escalation of cetuximab is well tolerated and may improve response and disease control rates, but patients experience ...

Chemo combination promising for multiple myeloma

May 02, 2012

(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response ...

Bevacizumab active in HIV-linked Kaposi's sarcoma

Mar 20, 2012

(HealthDay) -- For patients with HIV-associated Kaposi's sarcoma (HIV-KS), bevacizumab is tolerated and induces a response in some patients, according to a study published online March 19 in the Journal of ...

Tivozanib exhibits antitumor activity in renal cancer

Apr 10, 2012

(HealthDay) -- The potent, selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, tivozanib, demonstrates antitumor activity and is well tolerated in patients with advanced/metastatic ...

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

22 hours ago

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.